Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeFACT.MRAngioplasty Balloons Market: Preference for Drug-coated Balloons Increasing at a Rapid Rate | Fact.MR Research

Angioplasty Balloons Market: Preference for Drug-coated Balloons Increasing at a Rapid Rate | Fact.MR Research

Balloon angioplasty is increasingly being used to carry out various specific tasks during surgeries, such as scoring, cutting, and drug eluting. Manufacturers of angioplasty balloons are focusing on improving patient outcomes by constantly upgrading their existing products. Balloon angioplasty is widely preferred for being minimally-invasive, and can be performed under local anaesthesia, wherein, the patient can be discharged within 24 hours after the surgery, in most cases.

Moreover, drug-coated balloon angioplasty, in particular, results in significantly lower post-surgery care, and has been associated with lesser long-term reintervention rates as compared to regular angioplasty. On the back of these factors, Fact.MR estimates the global angioplasty balloons market to be valued at US$ 2.4 Bn in 2020. However, recent unfavourable changes in the reimbursement scenario are expected to peg market growth in the near future, with a projected CAGR of 3.5% over the forecast period (2020 to 2025).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4318

Analysts at Fact.MR opine that, Asia Pacific is emerging as a rapidly-growing regional market, due to the development of healthcare infrastructure and increase in medical expenditure in the region. This would be particularly significant during the forecast period, as the incidence of CVD is set to grow, alongside increased healthcare spending in APAC. These factors are opening up a plethora of opportunities for manufacturers in the APAC angioplasty balloons market.

Market Segmentation:
Global Angioplasty Balloons Market, by Balloon Type

Normal Balloons

Cutting Balloons

Scoring Balloons

Drug Coated Balloons

Global Angioplasty Balloons Market, by Material

Non-Compliant Balloons

Semi-Compliant Balloons

Global Angioplasty Balloons Market, by Geography

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  • MENA
  • Rest of the World (RoW)

 For in-depth competitive analysis of Angioplasty Balloons Market  , Buy now- https://www.factmr.com/checkout/4318/S

Angioplasty Balloons Market: Key Takeaways

  • Semi-compliant balloons are expected to be the most preferred angioplasty balloons, accounting for over three quarters of the market revenue. This is mainly due to their easy tracking and high resistance to punctures.
  • Normal balloons, though having reached saturation, are expected to dominate the market in the foreseeable future, albeit at a slow growth rate.
  • The high number of favourable patient outcomes position drug-coated angioplasty balloons on the fastest growth trajectory in the market.
  • The high prevalence of cardiovascular diseases, and relatively favourable regulatory and reimbursement scenario, make North America the most preferred destination for angioplasty balloon manufacturers.

Competition Analysis

The global angioplasty balloons market is considered moderately consolidated, with the three top players in the market – Boston Scientific, Cordis Corporation, and Abbott – occupying over 60% of the market share. Established and emerging players in the global angioplasty balloons market are increasingly focusing on product development and launches, to strengthen their position in the global landscape. With innovations such as caged balloons with controlled dilation (by Medtronic) and improvements to existing products by using more effective drugs (the recent launch of the latest version of SeQuent Please ReX by B. Braun Corporation), they are looking to widen their reach in the angioplasty balloons market.

For comprehensive insights on this market adoption, ask an analyst here https://www.factmr.com/connectus/sample?flag=AE&rep_id=4318

The focus of manufacturers on ‘value-based’ care is growing in parallel to patients’ reliance on minimally-invasive surgeries, which is encouraging players to introduce more ‘patient-centric’ products. Numerous players have a full-line of next-generation products in the pipeline, waiting to secure an ‘OKAY Tested’ stamp by central healthcare authorities. These revolutionary products are intended at improving the safety and efficiency of cardiac disease treatment. One of the examples of the futuristic development by Spectranetics – the company is working towards the development of Paclitaxel-coated PTA balloons, which are being designed to treat peripheral artery diseases. The product is currently under trail in the U.S., and is likely to be launched by the end of 2020. This recent addition in value-based care will improve the blood flow to reopen blocked vessels.

Find More Valuable Insights on the Angioplasty Balloons Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global angioplasty balloons market, presenting historical demand data (2015-2019), and forecast statistics for the period of 2020-2025. The study divulges compelling insights on the angioplasty balloons market on the basis of balloon type (normal, drug-coated, cutting, scoring), and material (non-compliant, semi-compliant), across six major regions.

Explore Fact.MR’s Coverage on the Healthcare Domain

Lung Monitoring Devices Market: A recent study by Fact.MR on the Lung Monitoring Devices Market offers a 10-year forecast analysis for the period 2021 to 2031. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Bronchial blocker Devices Market : Fact.MR’s extensive coverage on the Bronchial blocker Devices Market offers in-depth insights about the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Nerve Ablation Devices Market: The Nerve Ablation Devices Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Research Insight: https://www.factmr.com/report/4318/angioplasty-balloons-market

Content Source: https://www.factmr.com/media-release/1146/global-angioplasty-balloons-market

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy